Capitolis Liquid Global Markets LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 58.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 576,000 shares of the biopharmaceutical company’s stock after purchasing an additional 212,000 shares during the quarter. Capitolis Liquid Global Markets LLC’s holdings in Gilead Sciences were worth $70,698,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in the company. Paulson Wealth Management Inc. increased its holdings in shares of Gilead Sciences by 1.8% during the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares in the last quarter. Essex Financial Services Inc. increased its holdings in shares of Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 71 shares in the last quarter. Alpha Cubed Investments LLC increased its holdings in shares of Gilead Sciences by 1.1% during the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares in the last quarter. Personal CFO Solutions LLC increased its holdings in shares of Gilead Sciences by 1.7% during the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 76 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 1.7% during the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 76 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the completion of the sale, the insider owned 124,234 shares of the company’s stock, valued at $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the sale, the chief executive officer directly owned 617,567 shares of the company’s stock, valued at $81,185,357.82. The trade was a 2.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 68,000 shares of company stock valued at $8,930,150. 0.30% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
View Our Latest Report on Gilead Sciences
More Gilead Sciences News
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: The FDA accepted Gilead’s filing for once-weekly oral Yeztugo for HIV prevention, a key step that could expand the company’s long-acting PrEP franchise and create a new growth opportunity if approved. FDA Accepts Gilead’s Filing for Weekly Oral Yeztugo for HIV Prevention
- Positive Sentiment: Cantor Fitzgerald reaffirmed its Overweight rating and set a $155 price target, indicating analyst confidence in upside from current levels. Benzinga report on Cantor Fitzgerald rating
- Positive Sentiment: Gilead donated more than 2,000 vials of remdesivir to Uganda to support Ebola response efforts, which may help reinforce the company’s public-health profile, though the direct financial impact appears limited. Gilead Sciences Donates Remdesivir to Uganda
- Neutral Sentiment: Two senior insiders, including CFO Andrew D. Dickinson and executive Johanna Mercier, sold shares under pre-arranged 10b5-1 plans. These sales are routine and not necessarily a bearish signal, but they can still pressure sentiment. SEC filing for Andrew D. Dickinson sale SEC filing for Johanna Mercier sale
- Neutral Sentiment: The stock had recently been under mild pressure and is still trading below key moving averages, so the latest move looks more like a reaction to the mixed news flow than a change in fundamentals. Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
Gilead Sciences Price Performance
Shares of NASDAQ GILD opened at $125.45 on Thursday. The firm has a market cap of $155.75 billion, a PE ratio of 17.09 and a beta of 0.31. The firm has a fifty day moving average of $132.31 and a 200 day moving average of $134.30. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. Gilead Sciences, Inc. has a one year low of $104.46 and a one year high of $157.29.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.
Gilead Sciences Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s payout ratio is presently 44.69%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Articles
- Five stocks we like better than Gilead Sciences
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
